Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 3, 2011, Pages 274-278

  Cetin, Bulent ^a   Coskun, Ugur ^a   Yildiz, Ramazan ^a   Buyukberber, Suleyman ^a   Baykara, Meltem ^a   Benekli, Mustafa ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

cholecystitis; Everolimus; metastatic; mTOR inhibitor; renal cell carcinoma; toxicity

Indexed keywords

ANTIBIOTIC AGENT; EVEROLIMUS;

ABDOMEN; ACUTE CHOLECYSTITIS; ADULT; ARTICLE; CASE REPORT; CHOLELITHIASIS; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GALLBLADDER; HOSPITAL ADMISSION; HUMAN; KIDNEY CARCINOMA; LABORATORY TEST; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PAIN; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; CHOLECYSTITIS, ACUTE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 80053310214     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210363317     Document Type: Article

References (24)

1. Schmelzle T., Hall MN TOR, a central controller of cell growth. Cell 2000 ; 103: 253-262.
2. Fingar DC, Richardson CJ, Tee AR, Cheatham L., Tsou C., and Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation factor 4E. Mol Cell Biol 2004 ; 24: 200-216. (Pubitemid 38010048)
3. Hudson CC, Liu M., Chiang GC, Otterness DM, Loomis DC, Kaper F., et al. Regulation of hypoxia-inducible factor expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002 ; 22: 7004-7014.
4. Harding MW Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 2003 ; 9: 2882-2886. (Pubitemid 36993244)
5. Thomas GV, Tran C., Mellinghoff IK, Welsbie DS, Chan E., Fueger B., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006 ; 12: 122-127. (Pubitemid 43050086)
6. Yu K., Toral-Barza L., Discafani C., Zhang WG, Skotnicki J., Frost P., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001 ; 8: 249-258. (Pubitemid 32947647)
7. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004 ; 18: 1926-1945. (Pubitemid 39071573)
8. Del Bufalo D., Ciuffreda L., Trisciuoglio D., Desideri M., Cognetti F., Zupi G., et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006 ; 66: 5549-5554. (Pubitemid 43927103)
9. Pantuck AJ, Zeng G., Belldegrun AS, and Figlin RA Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003 ; 9: 4641-4652. (Pubitemid 37323266)
10. De Simone P., Carrai P., Petrucelli S., Baldoni L., Balzano E., Petrucelli S., et al. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function. Transpl Int 2009 ; 22: 279-286.
11. O' Donnell A., Faivre S., Burris III HA, Rea D., Papadimitrakopoulou V., Shand N., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008 ; 26: 1588-1595.
12. Corradetti MN, Guan KL Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 2006 ; 25: 6347-6360. (Pubitemid 44582281)
13. Mamane Y., Petroulakis E., LeBacquer O., and Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006 ; 25: 6416-6422. (Pubitemid 44582285)
14. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 ; 356: 2271.
15. Wood L., Bukowski RM, Dreicer R., Elson P., Garcia JA, Gilligan T., et al. Temsirolimus in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients previously treated with VEGF-targeted therapy (abstract). J Clin Oncol 2008 ; 26 (suppl): 16067.
16. Bellmunt J., Szczylik C., Feingold J., Strahs A., Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008 ; 19: 1387-1392.
17. UpToDate, Inc. Temsirolimus Drug Information 2009. Available at: www.uptodate.com (accessed on 11 December 2009 ).
18. Amato RJ, Jac J., Glessinger S., Saxena S., and Willis JP A phase II study of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma. Cancer 2009 ; 1 ; 115: 2438-2446.
19. Naranjo CA, Busto U., Sellers EM, Sandor P., Ruiz I., Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 ; 30: 239-245. (Pubitemid 12149145)
20. Wang HH, Portincasa P., and Wang DQ Molecular pathophysiology and physical chemistry of cholesterol gallstones. Front Biosci 2008 ; 13: 401-423. (Pubitemid 351599753)
21. Ma KL, Ruan XZ, Powis SH, Chen Y., Moorhead JF, Varghese Z., et al. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007 ; 84: 1029-1036. (Pubitemid 350287384)
22. Motzer RJ, Escudier B., Oudard S., Hutson TE, Porta C., Bracarda S., et al. On behalf of the RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 ; 372: 449-456.
23. Bhojani N., Jeldres C., Patard JJ, Perrotte P., Suardi N., Hutterer G., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008 ; 53: 917-930.
24. Bramow S., Ott P., Thomsen Nielsen F., Bangert K., Tygstrup N., and Dalhoff K. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin). Pharmacol Toxicol 2001 ; 89: 133-139. (Pubitemid 32905243)